➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Boehringer Ingelheim
Mallinckrodt
Baxter
Express Scripts

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for RDEA3170


Email this page to a colleague

« Back to Dashboard

What is the drug development status for RDEA3170?

RDEA3170 is an investigational drug.

There have been 15 clinical trials for RDEA3170. The most recent clinical trial was a Phase 2 trial, which was initiated on May 28th 2017.

The most common disease conditions in clinical trials are Gout, Hyperuricemia, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are Ardea Biosciences, Inc., AstraZeneca, and PAREXEL Early Phase Clinical Unit Baltimore.

There are fourteen US patents protecting this investigational drug and one hundred and eighty-nine international patents.

Recent Clinical Trials for RDEA3170
TitleSponsorPhase
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UAAnalytical Laboratory (Pharmacokinetic Sample Analysis): USAPhase 2
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UAClinical Laboratory: USAPhase 2
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UAContract Research Organization: USAPhase 2

See all RDEA3170 clinical trials

Clinical Trial Summary for RDEA3170

Top disease conditions for RDEA3170
Top clinical trial sponsors for RDEA3170

See all RDEA3170 clinical trials

US Patents for RDEA3170

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RDEA3170   Get Started Free 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same ARDEA BIOSCIENCES, INC. (San Diego, CA)   Get Started Free
RDEA3170   Get Started Free Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN)   Get Started Free
RDEA3170   Get Started Free Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN)   Get Started Free
RDEA3170   Get Started Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Get Started Free
RDEA3170   Get Started Free URAT1 inhibitor Nippon Chemiphar Co., Ltd. (Tokyo, JP) J-Pharma Co., Ltd. (Kanagawa, JP) DeThree Res. Lab. Inc. (Ibaraki, JP)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for RDEA3170

Drugname Country Document Number Estimated Expiration Related US Patent
RDEA3170 Australia AU2012332154 2031-11-03   Get Started Free
RDEA3170 Brazil BR112014010495 2031-11-03   Get Started Free
RDEA3170 Canada CA2852490 2031-11-03   Get Started Free
RDEA3170 China CN104023723 2031-11-03   Get Started Free
RDEA3170 China CN106963761 2031-11-03   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Harvard Business School
Colorcon
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.